scholarly journals EVOLUTION OF TYROSINE KINASE RESISTANCE IN EGFR MUTATED NON-SMALL CELL LUNG CANCER

2018 ◽  
Vol 19 (2) ◽  
pp. 106-116 ◽  
Author(s):  
Fedor Moiseenko
Keyword(s):  
Lung Cancer ◽  
Tyrosine Kinase ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Egfr Mutated

Genetic evolution to tyrosine kinase inhibitory therapy in patients with EGFR-mutated non-small-cell lung cancer

2021 ◽  
Author(s):  
Alex Martinez-Marti ◽  
Enriqueta Felip ◽  
Francesco Mattia Mancuso ◽  
Ginevra Caratú ◽  
Judit Matito ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Tyrosine Kinase ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Genetic Evolution ◽  
Small Cell Lung ◽  
Egfr Mutated

Treatment sequence of first and second generation tyrosine kinase inhibitor followed by osimertinib in EGFR-mutated non-small-cell lung cancer: a real life study

2020 ◽  
Vol 16 (16) ◽  
pp. 1115-1124
Author(s):  
Nicolas Girard ◽  
Denis Moro-Sibilot ◽  
Stéphane Bouée ◽  
Corinne Emery ◽  
Elodie Torreton ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Tyrosine Kinase ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Second Generation ◽  
Real Life ◽  
Small Cell ◽  
Small Cell Lung ◽  
First Line ◽  
Egfr Mutated

Background: We aimed to assess the effectiveness and cost of patients with first line tyrosine kinase inhibitors (TKIs) sequence of first (1G) and second generation (2G) followed by osimertinib. Materials & methods: Using the French nationwide claims and hospitalization database, we analyzed non-small-cell lung cancer patients who had been treated with osimertinib between April 2015 and December 2017, after a first line treatment with a TKI-1G/2G. Results: The median time on treatment for sequential TKI-1G/2G followed by osimertinib was 34 months (95% CI: 31–46); 13 and 12months, respectively for TKI 1G or 2G and TKI 3G, respectively. The median overall survival for sequential TKI 1G or 2G followed by osimertinib was 37 months (95% CI: 34–42). The mean monthly costs per patient was €5162. Conclusion: These results, in line with those observed during clinical trials, confirm the effectiveness of the sequence TKI-1G/2G followed by osimertinib in EGFR-mutated non-small-cell lung cancer.

scholarly journals FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring, and Management

Biomolecules ◽  
2019 ◽  
Vol 9 (11) ◽  
pp. 668 ◽  
Author(s):  
Isabelle Solassol ◽  
Frédéric Pinguet ◽  
Xavier Quantin
Keyword(s):  
Lung Cancer ◽  
Plasma Concentration ◽  
Tyrosine Kinase ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Clinical Decision Making ◽  
Primary Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Egfr Mutated

Non-small-cell lung cancer (NSCLC) is the most common form of primary lung cancer. The discovery of several oncogenic driver mutations in patients with NSCLC has allowed the development of personalized treatments based on these specific molecular alterations, in particular in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene. Gefitinib, erlotinib, afatinib, and osimertinib are TK inhibitors (TKIs) that specifically target EGFR and are currently approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) as first line treatment for sensitive EGFR-mutant patients. However, these four drugs are associated with severe adverse events (AEs) that can significantly impact patient health-related quality of life and patient monitoring. EGFR-TKIs are commonly used together with other types of medication that can substantially interact. Here, we review approaches used for the management of TKI-AEs in patients with advanced NSCLC to promote the benefits of treatments and minimize the risk of TKI treatment discontinuation. We also consider potential TKI–drug interactions and discuss the usefulness of plasma concentration monitoring TKIs based on chromatographic and mass spectrometry approaches to guide clinical decision-making. Adjusting the most appropriate therapeutic strategies and drug doses may improve the performance therapy and prognosis of patients with advanced EGFR-mutated NSCLC.

The immune profile of EGFR-mutated non-small-cell lung cancer at disease onset and progression after tyrosine kinase inhibitors therapy

Immunotherapy ◽  
2018 ◽  
Vol 10 (12) ◽  
pp. 1041-1045 ◽  
Author(s):  
Caterina Fumagalli ◽  
Elena Guerini-Rocco ◽  
Davide Vacirca ◽  
Antonio Passaro ◽  
Filippo de Marinis ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Tyrosine Kinase ◽  
Small Cell Lung Cancer ◽  
Tyrosine Kinase Inhibitors ◽  
Cell Lung Cancer ◽  
Kinase Inhibitors ◽  
Disease Onset ◽  
Small Cell ◽  
Small Cell Lung ◽  
Egfr Mutated
Sign in / Sign up

Export Citation Format

Share Document